FDA Approves New Colon Cancer Drug
Vectibix Follows Chemotherapy for Colorectal Cancer That Has Spread
The most serious adverse events in the Vectibix studies included pulmonary
fibrosis (the formation of fibrous tissue in the lungs), severe skin
rashcomplicated by infections,
infusion reactions, abdominal pain, nausea, vomiting, and constipation.
The most common adverse events associated with the drug included skin rash,
fatigue, abdominal pain, nausea, and diarrhea.
Vectibix is made by Amgen, Inc. The drug company has committed to conduct a
postmarketing trial to show whether Vectibix improves patients' survival in
patients with fewer prior chemotherapies.